Oxford researchers vaccinated the first volunteer with a candidate aimed at Bundibugyo ebolavirus on 24 July. [E1] The dose went to a healthy adult in a Phase I study, the first time this construct entered a human body. [E1][E2] Fifty volunteers aged 18–55 are expected to take part. [E2] The trial measures safety and immune response.
Manufacturing has already run far ahead of evidence. The Serum Institute of India produced and stockpiled about 620,000 doses for potential future use and supplied 4,000 investigational doses for the trial. [E2] Those vials are physical preparedness, not an authorised vaccination programme. They can shorten a future deployment clock only if the clinical and regulatory clocks move too.
The outbreak clock is less patient. The World Health Organization counted 2,124 confirmed cases and 828 deaths in the Democratic Republic of Congo through 15 July, plus 20 cases and two deaths in Uganda. [E3] Its published total therefore lags the first Oxford injection by more than a week. Surveillance, confirmation and publication each consume time while transmission continues.
Phase I creates a hard allocation boundary. Investigators can study adverse events, dose tolerance and immune markers in healthy adults. They cannot infer that the candidate prevents infection or death in exposed communities. A warehouse full of investigational doses does not dissolve that boundary.
Scarcity appears in several forms. Trial volunteers, laboratory capacity, regulators and outbreak teams all have limited time. Holding the stock protects the evidence standard and avoids distributing a product with unknown benefit. Early field use could accelerate learning and access, but it would also complicate consent, attribution of adverse events and comparisons needed for a clear result.
The strongest null is encouragingly dull: the candidate proves safe enough to continue, produces measurable antibodies and still requires larger trials before health authorities use the stockpile. No public result yet establishes efficacy, emergency authorisation or allocation to Congo or Uganda. [E1][E2][E3] A fast factory can remove the manufacturing delay without removing the trial.
Preparedness usually fails because a needed product does not exist at scale. Here, hundreds of thousands of doses exist before the first safety readout. [E2] That inversion is an achievement with a cruel ledger attached. The vials are ready to move; the evidence is still one arm into its journey.